AR062583A1 - Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan - Google Patents
Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartanInfo
- Publication number
- AR062583A1 AR062583A1 ARP070103831A ARP070103831A AR062583A1 AR 062583 A1 AR062583 A1 AR 062583A1 AR P070103831 A ARP070103831 A AR P070103831A AR P070103831 A ARP070103831 A AR P070103831A AR 062583 A1 AR062583 A1 AR 062583A1
- Authority
- AR
- Argentina
- Prior art keywords
- valsartan
- gastro
- extended
- farmaco
- liberation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un sistema de suministro de fármaco gastro-retentivo de liberacion extendida de Valsartan. El sistema de suministro de fármaco contiene una porcion de liberacion que contiene el Valsartan, una porcion gastro-retentiva para retener el sistema de suministro de fármaco en el estomago y una porcion secundaria opcional para suministrar un pulso secundario de Valsartan. En otra modalidad, se proporciona una membrana desdoblada que se puede hinchar que comprende Valsartan para la administracion sostenida de Valsartan al tracto gastrointestinal superior de un paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82410406P | 2006-08-31 | 2006-08-31 | |
US86486906P | 2006-11-08 | 2006-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062583A1 true AR062583A1 (es) | 2008-11-19 |
Family
ID=38873137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103831A AR062583A1 (es) | 2006-08-31 | 2007-08-29 | Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100233253A1 (es) |
EP (1) | EP2061438A1 (es) |
JP (1) | JP2010502642A (es) |
AR (1) | AR062583A1 (es) |
CL (1) | CL2007002523A1 (es) |
PE (1) | PE20080907A1 (es) |
TW (1) | TW200819128A (es) |
WO (1) | WO2008027945A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196396A1 (en) * | 2004-02-11 | 2007-08-23 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
WO2009084040A1 (en) * | 2007-12-28 | 2009-07-09 | Rubicon Research Private Limited | Once a day formulation of angiotensin receptor blockers |
CN102046154A (zh) * | 2008-06-03 | 2011-05-04 | 诺瓦提斯公司 | 缬沙坦的脉冲释放 |
WO2015174684A1 (ko) * | 2014-05-14 | 2015-11-19 | 동아에스티 주식회사 | 방출제어된 위체류 서방성 제제 |
US10363288B2 (en) | 2015-01-14 | 2019-07-30 | National Jewish Health | Insulin mimotopes and methods of using the same |
WO2016192680A1 (en) * | 2015-06-03 | 2016-12-08 | Triastek, Inc. | Dosage forms and use thereof |
US9675585B1 (en) | 2016-03-24 | 2017-06-13 | Ezra Pharma | Extended release pharmaceutical formulations |
US9687475B1 (en) | 2016-03-24 | 2017-06-27 | Ezra Pharma Llc | Extended release pharmaceutical formulations with controlled impurity levels |
EP3634507A4 (en) * | 2017-06-07 | 2021-03-24 | EGY-Nano Pharma, LP | PROLONGED ORAL DRUG DELIVERY PLATFORMS |
CN111405895B (zh) * | 2017-12-29 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 一种控释药物组合物及其制备方法 |
WO2019137200A1 (en) | 2018-01-09 | 2019-07-18 | Triastek, Inc. | Oral drug dosage forms comprising a fixed-dose of an adhd non-stimulant and an adhd stimulant |
US11052060B2 (en) | 2018-02-12 | 2021-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and methods for treating autoimmunity |
US11013707B2 (en) | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
US11147767B2 (en) * | 2019-02-25 | 2021-10-19 | Rubicon Research Private Limited | Gastroretentive formulations |
US11389398B2 (en) | 2019-05-14 | 2022-07-19 | Clexio Biosciences Ltd. | Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
TW202233162A (zh) * | 2020-10-30 | 2022-09-01 | 大陸商南京三迭紀醫藥科技有限公司 | 胃滯留藥物劑型 |
WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
AU2003249492A1 (en) * | 2003-07-24 | 2005-02-14 | Eswaran Krishnan Iyer | Oral compositions for treatment of diseases |
WO2007079082A2 (en) * | 2005-12-30 | 2007-07-12 | Advancis Pharmaceutical Corporation | Gastric release pulse system for drug delivery |
TR201902010T4 (tr) * | 2006-01-18 | 2019-03-21 | Intec Pharma Ltd | Bir ajanın oral alımına yönelik taşıyıcı cihaz. |
WO2007086078A2 (en) * | 2006-01-30 | 2007-08-02 | Panacea Biotec Ltd. | Novel pharmaceutical compositions and process of preparation thereof |
-
2007
- 2007-08-28 PE PE2007001165A patent/PE20080907A1/es not_active Application Discontinuation
- 2007-08-29 JP JP2009526884A patent/JP2010502642A/ja not_active Withdrawn
- 2007-08-29 US US12/377,949 patent/US20100233253A1/en not_active Abandoned
- 2007-08-29 AR ARP070103831A patent/AR062583A1/es unknown
- 2007-08-29 WO PCT/US2007/077071 patent/WO2008027945A1/en active Application Filing
- 2007-08-29 EP EP07841511A patent/EP2061438A1/en not_active Withdrawn
- 2007-08-30 CL CL200702523A patent/CL2007002523A1/es unknown
- 2007-08-30 TW TW096132310A patent/TW200819128A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010502642A (ja) | 2010-01-28 |
US20100233253A1 (en) | 2010-09-16 |
EP2061438A1 (en) | 2009-05-27 |
CL2007002523A1 (es) | 2008-08-08 |
WO2008027945A1 (en) | 2008-03-06 |
PE20080907A1 (es) | 2008-08-22 |
TW200819128A (en) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062583A1 (es) | Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan | |
WO2010062688A3 (en) | Dosage form for insertion into the mouth | |
EP2444072A3 (en) | Non-mucoadhesive film dosage forms | |
RS51688B (en) | METHOTREXATE CONCENTRATED SOLUTIONS | |
WO2011079302A3 (en) | Swallowable drug delivery device and methods of drug delivery | |
ES2531215T3 (es) | Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos | |
RS52367B (en) | GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES | |
CO5690530A2 (es) | Sistema de suministro de farmacos | |
NZ601529A (en) | Tapentadol compositions | |
AR062167A1 (es) | Sistema de administracion gastrorretentivo | |
DE602007007991D1 (de) | Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung | |
CL2007001018A1 (es) | Inhalador para administrar un medicamento en forma de sustancias inhalables, formulaciones o mezclas de sustancias, comprende una carcasa que presenta un interior para lojar el medicamento, la carcasa esta unida de forma fija a una boquilla, ademas puede incorporar una aguja para perforar una capsula con medicamento. | |
MX2009005339A (es) | Suspensiones analgesicas de liberacion modificada. | |
WO2008058288A3 (en) | Sustained release methotrexate formulations and methods of use thereof | |
FR19C1030I1 (fr) | Systeme d'administration de medicament pour administrer des substances pharmaceutiquement actives pauvrement hydrosolubles | |
ATE468846T1 (de) | Magenresistente pharmazeutische dosierform mit n- (2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d- glutaminsäure (lk-423) | |
IL195931A0 (en) | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production | |
MX344778B (es) | Combinacion de medicamentos orales unidos por una envoltura. | |
NZ595376A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
EP2540294A4 (en) | SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION | |
PL2101730T3 (pl) | Postać galenowa do podawania drogą przezśluzkową paracetamolu | |
CL2008003584A1 (es) | Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva. | |
RU2007129408A (ru) | Способ выращивания поросят в период откорма | |
MX2009006735A (es) | Capsulas de gelatina que comprenden un acido. | |
EP2228056A3 (en) | Tolperisone controlled release tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |